No Widgets found in the Sidebar
A Unique Mammalian Suspension Technology Enhances Scalable rAAV Production with Pro10 Cell Line

A new technology, Pro10™, is being developed to improve the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology allows for scalable and robust production of rAAVs, addressing the challenges faced in large-scale manufacturing in AAV gene therapies.

Pro10™ cells have been fully characterized and licensed for gene therapy development by other biopharma companies. Viralgen utilizes these cells as the foundation for a robust and scalable rAAV vector manufacturing process. These cells have been optimized for rAAV production and successfully scaled up to 2000L, demonstrating consistent and reproducible cell growth rates. They exhibit similar productivity in small and large-scale bioreactors and can produce different AAV serotypes.

The Pro10™ cell line plays a crucial role in Viralgen’s platform process for manufacturing AAV vectors and has been vital in producing groundbreaking gene therapies. The HEK293 derived animal component-free suspension Pro10™ cell line is described in full in the PDF, which highlights its ability to reduce process development time and costs. This innovative technology is a promising advancement in the field of gene therapy manufacturing, offering a solution to the challenges faced in large-scale production of AAV vectors.

By Samantha Jones

As a dedicated content writer at, I bring a unique blend of creativity and precision to my work. With a passion for storytelling and a keen eye for detail, I strive to craft engaging and informative articles that captivate our readers. From breaking news to thought-provoking features, I am committed to delivering content that resonates with our audience and keeps them coming back for more. Join me on this exciting journey as we explore the ever-evolving world of news and information together.

Leave a Reply